sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol (Rx)

Brand and Other Names:Suclear
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

oral solution & powder for oral solution

  • Oral solution: (17.5g sodium sulfate/3.13g potassium sulfate/1.6g magnesium sulfate)/6oz
  • Powder for oral solution: (210g PEG-3350/5.6g sodium chloride/2.86g sodium bicarbonate/0.74g potassium chloride)/2 L
more...

Bowel Prep

Indicated for cleansing of the colon in preparation for colonoscopy

Administer as either a split dose (2-day) regimen (preferred method) or day-before (1-day) regimen

Split dose (2-day) regimen (preferred)

  • Dose 1 - Evening before the colonoscopy (10-12 hours prior to Dose 2)
  • a) Dilute 6-oz oral solution prior to use by pouring the entire contents of the bottle into the 16-oz mixing container and then filling the container with cool water to the fill line and mix
  • b) Drink the entire solution in the container, it is best to complete drinking the solution within 20 minutes
  • c) Refill the container with 16 oz of water to the fill line and drink it over the next 2 hours
  • d) Refill the container with 16 oz of water to the fill line and finish drinking it before going to bed
  • Dose 2 - Next morning on the day of the colonoscopy (start at least 3.5 hr prior to colonoscopy)
  • a) Dissolve the powder of Dose 2 by adding water to the fill line on the jug
  • b) Shake the jug until all the powder is dissolved (can be used with or without the addition of a flavor pack); when dissolved in water to a volume of 2 liters, the solution is clear and colorless; may be refrigerated after adding water and should be used within 48 hr of reconstitution
  • c) Using the 16-oz container provided with the kit, drink all the solution in the jug at a rate of one 16-oz container every 20 minutes (this is four 16-oz containers over a period of 1.5 hr)
  • d) Complete drinking the solution at least 2 hr before the colonoscopy
  • e) Consume only clear liquids until 2 hr prior to colonoscopy; thereafter, nothing should be consumed until the completion of colonoscopy

Day-before (1-day) regimen (alternative method)

  • On the evening before the colonoscopy: Dose 1 - (Begin at least 3.5 hr prior to bedtime)
  • a) Dilute the 6-oz oral solution prior to use by pouring the entire contents of the bottle into the 16-oz mixing container and then filling the container with cool water to the fill line and mix
  • b) Drink the entire solution in the container within 20 minutes
  • c) Refill the container with 16 oz of water to the fill line and drink it over the next 2 hr Dose 2 - (Approximately 2 hr after starting Dose 1)
  • d) Dissolve the powder of Dose 2 by adding water to the fill line on the jug
  • e) Shake the jug until all the powder is dissolved (can be used with or without the addition of a flavor pack); when dissolved in water to a volume of 2 liters, the solution is clear and colorless; may be refrigerated after adding water and should be used within 48 hr of reconstitution
  • f) Using the 16-oz container provided with the kit, drink all the solution in the jug at a rate of one 16-oz container every 20 minutes (this is four 16-oz containers over a period of 1.5 hr)
  • g) Refill the container with 16 oz of water to the fill line and finish drinking it before going to bed
  • h) Consume only clear liquids until 2 hr prior to colonoscopy; thereafter, nothing should be consumed until the completion of colonoscopy

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Abdominal distention (52%)

            Nausea (46%)

            Abdominal pain (38%)

            Vomiting (14%)

            High bilirubin (11%)

            1-10%

            High anion gap (10%)

            Low GFR (9%)

            High creatine kinase (7%)

            Low bicarbonate (4%)

            High calcium (4%)

            High osmolality (4%)

            Low potassium (4%)

            High uric acid (4%)

            Low Phosphate (3%)

            High creatinine (3%)

            Headache (2%)

            High glucose (2%)

            Low sodium (1%)

            Low chloride (1%)

            High creatinine (1%)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            GI obstruction or ileus

            Bowel perforation

            Gastric retention

            Toxic colitis or toxic megacolon

            Cautions

            Hydrate adequately before, during, and following to decrease risk of fluid and electrolyte abnormalities

            Rare reports of serious arrhythmias and seizures with use of osmotic bowel preparations

            Consider the risks in patients with impaired renal function or patients taking concomitant medications that may affect renal function (eg, diuretics, ACE inhibitors, ARBs, NSAIDs)

            Osmotic laxatives may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization

            Evaluate for GI obstruction, GI perforation, and aspiration risk before administration

            Ingestion of the undiluted solution may increase the risk of nausea, vomiting, dehydration or other serious adverse reactions

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Unknown whether distributed in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            The bowel evacuation effect is the result of the osmotic effect of unabsorbed PEG, sulfate anions and the associated cations which causes water to be retained within the gastrointestinal tract

            Absorption

            Bioavailability: 20% (oral sulfates)

            Peak plasma time: 5.5 hr (serum sulfate)

            Elimination

            Half-life: 8.5 hr (sulfates)

            Excretion: 80% feces

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous